Toxoplasma gondii is a ubiquitous intracellular parasite with an estimated seroprevalence of 22.5% in US residents aged 12 and older. Seroprevalence reaches 95% in some low-altitude countries with hot, humid climates. 1 Although seroprevalence is relatively common, invasive toxoplasmosis involving the central nervous system (CNS), lung, liver and myocardium after stem cell transplantation (SCT), provoked by defective cellular immunity, is infrequent (0.2-7.6%), especially in the era of sulfamethoxazole/ trimethoprim (Bactrim) prophylaxis. [2] [3] [4] In HIV-positive patients with toxoplasmic encephalitis (TE), the T-cell response can lead to rare instances of an immune reconstitution inflammatory response (IRIS). 5, 6 Here we describe the first documented case of IRIS in a SCT recipient.
A 21-year-old female with high-risk pre-B acute lymphoblastic leukemia with history of CNS disease underwent a haplo-identical allogeneic peripheral blood SCT with her mother serving as the donor. The conditioning regimen adopted a two-step approach, 7 including fludarabine 120 mg/m 2 , total body irradiation (12 Gy) and a donor lymphocyte infusion (2 × 10 8 /kg CD3 + T cells) followed by cyclophosphamide 120 mg/kg prior to CD34 + selected stem cell infusion. The subject then received sirolimus (trough goal 5 − 12 ng/mL) along with ultra-low-dose interleukin-2 (ULD-IL2) for GvHD prophylaxis (Clinicaltrial.gov: NCT02226861, NHLBI protocol: 14-H-0180). Written informed consent was obtained in accordance with the Declaration of Helsinki for research under the protocol approved by the Institutional Review Board of the National Heart, Lung, and Blood Institute.
Before transplant, both recipient and donor were seropositive for toxoplasmosis. The post-transplant course was complicated by GvHD of the liver, gastrointestinal, oral and ocular mucosa shortly after the ULD-IL2 was withdrawn on day +84 per protocol.
After day 100 post SCT, she was intermittently treated with ULD-IL2 and systemic steroids for recurrent liver GvHD flares. At that time, she developed personality changes, becoming emotionally labile and introverted. Seven months post SCT, she developed transaminitis shortly after again stopping ULD-IL2. This transaminitis was assumed to be a manifestation of GvHD, as the pattern was similar to her prior episodes. ULD-IL2 was restarted with methylprednisolone 1 mg/kg daily. Within 1 week she developed a progressive generalized headache, unresponsive to supportive treatments ( Figure 1a) . A head CT scan 2 weeks after resuming ULD-IL2 showed a 1.8 × 2.8 × 1.4 cm left thalamic and a 0.7 × 1.1 × 1.2 cm right caudate lesion. MRI also revealed multiple cortical lesions as well as a right medullary lesion ( Figure 1b) . On neurologic examination, she was apathetic and had right-sided dysesthesias and mild transient right-sided weakness corresponding to the left thalamic lesion. CSF was free of leukemic cells but polymerase chain reaction (PCR) assay was strongly positive at cycle 26 for T. gondii, confirming the diagnosis of TE. Treatment with pyrimethamine 50 mg daily, leucovorin 25 mg daily and sulfadiazine 1000 mg every 6 h was initiated. This event occurred despite reported compliance with Bactrim.
Despite decreasing parasite burden by PCR (positive at cycle 37) on serial lumbar punctures, a tonic-clonic generalized seizure occurred on day 10 of hospitalization and MRI demonstrated new hemorrhage into several pre-existing brain lesions, which had increased in size and now were associated with edema and leptomeningeal enhancement, consistent with an inflammatory response (Figure 1b) . A subsequent brain biopsy showed perivascular lymphocyte infiltration with hemorrhage and partial necrosis but absence of residual toxoplasmosis (Figures 2a and b) . Abundant CD4 + and CD8 + cell infiltration was observed with a population of cytotoxic T lymphocytes highlighted by TIA-1, granzyme B and perforin immunostaining (Figures 2c and d ). There were extremely low numbers of regulatory T cells immunostained with antibodies to CD25 and FoxP3. Stains for toxoplasmosis, EBV and other infectious etiologies and markers of leukemia (CD22, CD79a and CD10) were negative. PCR of the brain tissue was positive for T. gondii. Collectively, these findings support a diagnosis of TE with clinical deterioration due to IRIS. Dexamethasone 4 mg every 6 h was initiated. Owing to concerns that the oral anti-toxoplamosis drugs were not penetrating the lesions, sulfadiazine was changed to intravenous Bactrim 5 mg/kg every 8 h and clindamycin 900 mg every 8 h was added.
Following reintroduction of ULD-IL2, peripheral CD4 + and CD8 + cells increased dramatically (Figure 1a) . Peak lymphocyte counts corresponded to the highest level of inflammation seen on MRI and to her clinical seizure. Attribution of ULD-IL2 as a provoking agent for IRIS was considered and prompted its discontinuation. Thereafter, the patient showed gradual clinical improvement and slow regression of her MRI abnormalities (Figure 1b ). Oral sulfadiazine, pyrimethamine and leucovorin were reintroduced and dexamethasone was tapered off. She was discharged from the hospital 40 days after the initiation of toxoplasma treatment. At the last follow-up 10 months post SCT, she could independently care for herself and her neurological symptoms have dramatically improved except for minimal residual right-sided dysesthesias.
TE is an infrequent (incidence rates 1-7.6%) complication of allogeneic bone marrow transplant patients but carries high mortality (90%). 4, 8, 9 Most cases are diagnosed at autopsy, but, if cases are identified and patients are appropriately treated, 60% will improve. 3, [8] [9] [10] Major risk factors for TE in the SCT population are allogeneic transplant, positive pre-transplant toxoplasma serology, prior GvHD and CD4 T cells o200/μL. [2] [3] [4] 9 Our patient possessed all four risk factors at the time of her diagnosis. Depending on the level of immunosuppression, SCT patients may not show the typical MRI findings of ring enhancement or perilesional edema. 8 After SCT, TE is usually caused by reactivation of latent tissue cysts.
2-4,9 T. gondii opportunistically infects all cells within the CNS, upregulating pro-inflammatory cytokines, which initiate a host cascade of immune-mediated destruction against the disseminating tachyzoite. This results in tissue destruction and lesion necrosis, 11 but this intracellular survival strategy and immune evasion by bradyzoites allow for long-term survival of the parasite. 6 Bradyzoites survive in a dormant intracellular phase and tissue cysts are suppressed by a Th1 immune response. 6 Macrophages and dendritic cells produce IL-12, which stimulates CD4 + cells to release IL-2, INF-γ, IL-6 and TNF-α, resulting in a reactive oxygen-and nitric oxide-mediated cytotoxic response. IRIS is an excessive, tissue-damaging inflammatory response to a pre-existing antigen or pathogen that produces a paradoxical deterioration in clinical status. 12 Despite much research, its pathogenesis is largely unknown and there is no concordance about a unifying case definition. It is hypothesized that, in HIV/AIDS patients, there is an unbalanced reconstitution of levels of IFN-γ and decreased IL-2 production lead to uncontrolled T. gondii growth and ultimately to abscess formation with necrotic centers and hyperemic edges (ring-enhancing lesions). Imaging typically demonstrates multiple ring-enhancing lesions, along with peri-lesional edema. Brain biopsies of TE-IRIS lesions have shown peri-vascular lymphocytic infiltrates, with CD8 + cell predominance.
Our patient was enrolled on a protocol where ULD-IL2 was started at the time of transplant. In vivo and in vitro studies show that ULD-IL2 expands Tregs and natural killer cells (NKs), both of which suppress T-cell-mediated immunity. 13 We hypothesize that deprivation of IL-2 following withdrawal of supplemented ULD-IL2 may have precipitated TE in our patient similar to the patients with HIV/AIDS patients. The subsequent re-introduction of ULD-IL2 together with rapid steroid tapering corresponded to a significant rise of peripheral CD4 + and CD8 + cells, similar to what is seen with spontaneous cases of IRIS in the HIV population. This lymphocyte surge may have precipitated an IRIS-like response at established foci of toxoplasmosis lesions.
14, 15 We, therefore, conclude that the unusual occurrence of IRIS in our patient with TE post SCT may have been provoked by dynamic immunological unbalance of overactivated T-cells and Tregs in the setting of GvHD and ULD-IL2 treatment. Further in vitro study is needed to confirm our hypothesis and to address the homeostatic roles of IL-2 in Toxoplasma immunity.
